Loading
CT
Clarus Therapeutics Holdings, Inc. Stock: price and insider trades · United States
Clarus Therapeutics Holdings, Inc.: what insiders have been doing
Clarus Therapeutics Holdings, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at Clarus Therapeutics Holdings, Inc. has published a filing in the past twelve months. The most recent one dates from 9 June 2022.
Since 2021, the database holds no purchases and 7 sales by insiders of the company.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
33
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€10M
7 ops. · all time
Analyst consensus: bullish or bearish?
Analysts rate Clarus Therapeutics Holdings, Inc. Hold (neutral), based on 1 analysts. Average price target: US$3.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Analyst consensus
1 analystsHold
US$3.00Target US$3.00US$3.00
Income statement
RevenueUS$12.4M
Gross profitUS$10M81% margin
Net income-US$36.2M-291.0% margin
Last declaration on 9 June 2022
Declarations33 total
1,922 shares0Common StockSEC:0000899243-22-021749:0
1,922 shares0Common StockSEC:0000899243-22-021755:0
1,922 shares0Common StockSEC:0000899243-22-021756:0
1,922 shares0Common StockSEC:0000899243-22-021760:0
1,922 shares0Common StockSEC:0000899243-22-021761:0
1,237,500 shares0Common StockSEC:0001213900-22-021910:1
65,000 shares0Common StockSEC:0001213900-22-021910:0
2,061,685 shares@ US$2.53Common StockSEC:0001062993-22-010736:1
5,722 shares@ US$2.53Common StockSEC:0001062993-22-010736:2
13,630 shares@ US$2.53Common StockSEC:0001062993-22-010736:3
1,164 shares@ US$2.53Common StockSEC:0001062993-22-010736:4
7,585 shares@ US$2.53Common StockSEC:0001062993-22-010736:5
1,663,126 shares@ US$2.53100.0% of flowCommon StockSEC:0001062993-22-010736:0
29,000 shares0Common StockSEC:0000899243-21-048203:0
3,844 shares0Common StockSEC:0000899243-21-048205:0
55,800 shares0Common StockSEC:0000899243-21-048204:0
3,844 shares0Common StockSEC:0000899243-21-048207:0
3,844 shares0Common StockSEC:0000899243-21-048202:0
29,000 shares0Common StockSEC:0000899243-21-048212:0
3,844 shares0Common StockSEC:0000899243-21-048213:0
3,844 shares0Common StockSEC:0000899243-21-048208:0
135,000 shares0Common StockSEC:0000899243-21-048206:0
2,731,094 shares0Common StockSEC:0001013762-21-000025:1
2,470,756 shares0Common StockSEC:0001013762-21-000025:2
490,531 shares0Common StockSEC:0001013762-21-000025:0
25 of 33 declarations
About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. (ticker: CRXT) is a United States-based specialty pharmaceutical company listed on a NYSE/NASDAQ venue, with a business profile centered on men’s health and testosterone replacement therapy. The company’s roots go back to 2004, when Clarus Therapeutics was founded in Northbrook, Illinois. Its current corporate structure was created in September 2021, when the legacy Clarus business completed a merger with Blue Water Acquisition Corp., a SPAC transaction that resulted in the renaming of the combined entity to Clarus Therapeutics Holdings, Inc. The company remains headquartered in Northbrook, Illinois, keeping its operational base in the U.S. Midwest. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312522092120/d288074d10k.htm))
From a business standpoint, Clarus is a focused commercialization-stage pharmaceutical company whose core and historically sole revenue driver has been JATENZO, an oral testosterone replacement therapy. According to SEC disclosures, JATENZO was launched commercially in February 2020 after FDA approval in March 2019. Management has described it as the first and only oral TRT of its kind approved by the FDA, which gives Clarus a differentiated position in a market dominated by injectable and topical testosterone products. The company’s sales have been reported as exclusively within the United States, so the commercial footprint is highly concentrated and domestically oriented. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312522092120/d288074d10k.htm))
Read moreShow less
In competitive terms, Clarus operates in a crowded therapeutic area where scale, physician familiarity, payer access, and patient adherence all matter. Its strategic advantage lies in formulation differentiation rather than broad product breadth. An oral administration profile can be attractive for certain patients and prescribers, but the company also faces the classic risks of a single-product specialty pharma model: concentration risk, regulatory dependence, and execution risk in a market with entrenched alternatives. SEC filings also note recurring operating losses and periodic disclosures around going-concern considerations and the need for additional financing, underscoring the company’s financially fragile, situation-specific nature. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1817944/000119312521366306/d262025d424b3.htm))
Recent corporate context remains tied to U.S. SEC reporting and insider activity, including Form 4 filings that reflect the movement of stock ownership by officers, directors, and large holders. For investors, that makes CRXT a name that is best assessed through a special-situations lens: product commercialization, balance-sheet resilience, and the sustainability of JATENZO’s U.S. revenue base matter more than portfolio diversification. In short, Clarus Therapeutics Holdings, Inc. is a small-cap U.S. specialty pharma company with a niche oral TRT franchise, a Northbrook, Illinois headquarters, and a high-risk/high-uncertainty investment profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001817944/000101376221000025/xslF345X03/ownership.xml?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
